KALA BIO Provides CEO Update and Preliminary Third Quarter 2026 Financial Results
New York, New York--(Newsfile Corp. - November 9, 2026) - KALA BIO, Inc. (NASDAQ: KALA) today announced preliminary unaudited financial results for the quarter ended September 30, 2026. Preliminary Third Quarter 2026 Results Net loss of approximately $0.8 million for the third quarter of 2026, compared to $7.6 million for the third quarter of 2025. Net loss of approximately $4.0 million for the nine months ended September 30, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-09 8:00 AM EST | KALA Bio Inc.
Phio Pharmaceuticals Announces e-Presentation at American Society for Dermatologic Surgery (ASDS) Annual Meeting
King of Prussia, Pennsylvania--(Newsfile Corp. - November 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that clinical data from its Phase 1b trial were presented at the 2026 Annual Meeting of the American Society for Dermatologic Surgery (ASDS), held in San Diego, California, from November 5-8, 202
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-09 7:00 AM EST | Phio Pharmaceuticals Corp.
Alenura Delivers Positive Phase 2 Results in Interstitial Cystitis/Bladder Pain Syndrome Trial
New Brunswick, New Jersey--(Newsfile Corp. - November 9, 2026) - Vaneltix Pharma, Inc. ("Vaneltix"), a biotechnology company focused on developing treatments addressing unmet needs in women's healthcare and urology and Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) ("Hyloris") , the specialty pharma group committed to addressing unmet medical needs through reinventing existing medicines and smart NCE developments, today announce positive and statistically significant Phase
Biotechnology, Pharmaceuticals
2026-11-09 7:00 AM EST | Vaneltix Pharma Inc.
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
King of Prussia, Pennsylvania--(Newsfile Corp. - November 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that it will present clinical data from its Phase 1b clinical trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Phoenix, Arizona from Novem
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-06 9:05 AM EST | Phio Pharmaceuticals Corp.
BetterLife Pharma Announces Settlement of Claim with Dr. Steven Sangha
Vancouver, British Columbia--(Newsfile Corp. - November 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that it has entered into a settlement agreement dated November 5, 2026 (the "Settlement Agreement"
2026-11-06 8:00 AM EST | BetterLife Pharma Inc.
Custom Health Files Final Short Form Base Shelf Prospectus
Kelowna, British Columbia--(Newsfile Corp. - November 5, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Corporation") is pleased to announce that it has filed and received a receipt for its final short form base shelf prospectus (the "Final Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The Final Prospectus permits the Corporation, if it so chooses, to offer up to $200
Technology, Pharmaceuticals, Health
2026-11-05 5:59 PM EST | Custom Health Holdings Inc.
Extendicare Announces 2026 Third Quarter Results
Markham, Ontario--(Newsfile Corp. - November 5, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and nine months ended September 30, 2026. Third Quarter 2026 Highlights Adjusted EBITDA(1) of $71.7 million, up $20.9 million or 41.2% from Q3 2025. Net earnings of $34.2 million ($0.354 per diluted share), up $10.1 million or 41.8% from $24.1 million ($0.
Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-05 5:00 PM EST | Extendicare Inc.
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
King of Prussia, Pennsylvania--(Newsfile Corp. - November 5, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage biopharmaceutical company developing therapeutic products based on its proprietary INTASYL® gene-silencing technology to eliminate cancer, today reported financial results for the quarter ended September 30, 2026, and provided a business update. "We have successfully executed on critical development objectives to advance the PH-762 program towa
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-05 4:05 PM EST | Phio Pharmaceuticals Corp.
InMed Announces Expected Closing of Merger and Commencement of Trading on Nasdaq Under the Name "Mentari Therapeutics, Inc." and Ticker Symbol "MTRI"
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, subject to the satisfaction or waiver of the remaining closing conditions under the agreement and plan of merger and reorganization dated May 19, 2026 (
Biotechnology, Pharmaceuticals
2026-11-05 4:01 PM EST | Mentari Therapeutics, Inc.
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - November 5, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an emerging biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced that Ralph Anthony ("Tony") Pullen has resigned from the Company's Board of Directors, effective November 4, 2026, and will remain with the Company as an advisor. The Board has appointed Henry Chow, CPA, CA, as a d
2026-11-05 8:00 AM EST | BetterLife Pharma Inc.
InMed Announces Results of 2026 Annual General and Special Meeting, Approval of Corporate Name Change and Completion of Share Consolidation
Vancouver, British Columbia--(Newsfile Corp. - November 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, confirmed that, at its annual general and special meeting of shareholders held today (the "Meeting"), the matters put forward before shareholders for consideration and appr
Biotechnology, Pharmaceuticals
2026-11-04 4:51 PM EST | Mentari Therapeutics, Inc.
Medexus Schedules Second Fiscal Quarter 2027 Conference Call
Ontario and Chicago, Illinois--(Newsfile Corp. - November 3, 2026) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, November 12, 2026, to discuss Medexus's results for its second fiscal quarter ended September 30, 2026. Medexus expects to file its financial statements and MD&A after markets close on November 11, 2026. To participate in the call, please dial the following numbers:
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-03 5:27 PM EST | Medexus Pharmaceuticals Inc.
Custom Health Files Preliminary Short Form Base Shelf Prospectus and Refiles Certain Continuous Disclosure Documents
Kelowna, British Columbia--(Newsfile Corp. - November 3, 2026) - Custom Health Holdings Inc. (TSX: CHLT) ("Custom Health" or the "Corporation") is pleased to announce that it has filed a preliminary short form base shelf prospectus with the securities commissions in each of the provinces and territories of Canada. The base shelf prospectus, when made final and effective, will allow the Corporation to qualify the distribution by way of prospectus in
Technology, Pharmaceuticals, Health
2026-11-03 5:00 PM EST | Custom Health Holdings Inc.
InMed Reports First Quarter Fiscal 2027 Financial Results and Provides Corporate Update
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its first quarter of fiscal 2027, ended September 30, 2026, and provided a corporate update. The Company's full financial statements and related MD&A for th
Biotechnology, Pharmaceuticals
2026-11-03 7:30 AM EST | Mentari Therapeutics, Inc.
Elite Pharmaceuticals Expands Board of Directors with Election of Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq.
Northvale, New Jersey--(Newsfile Corp. - November 3, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that on October 28, 2026, its Board of Directors (the "Board") increased the size of the Board from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq. as directors. "We are pleased to welcome Aqeel Fatmi and John LaRocca to
Healthcare and Hospitals, Pharmaceuticals, Health
2026-11-03 7:30 AM EST | Elite Pharmaceuticals, Inc.
Herbal Dispatch Accelerates Veteran Program Growth and Expands Access with New Clinic Partnership
Vancouver, British Columbia--(Newsfile Corp. - November 3, 2026) - Herbal Dispatch Inc. (CSE: HERB) (OTCQB: LUFFF) (FSE: HA9) ("Herbal Dispatch" or the "Company"), a cannabis commerce and international distribution platform, today issued a progress report on Hero Dispatch (herodispatch.com), the Company's medical cannabis program for Canadian Veterans, and highlighted the continued expansion o
Pharmaceuticals, Cannabis, Cannabis Dispensary
2026-11-03 5:00 AM EST | Herbal Dispatch Inc.
Neural Therapeutics Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - November 2, 2026) - Neural Therapeutics Inc. (CSE: NURL) (FSE: HANF) ("Neural" or the "Company") announces a change to its Board of Directors and provides updates regarding its previously announced transaction with CWE European Holdings Inc. ("CWE"). Board of Directors The Company announces that John Durfy has resigned as Chairman and a director of the Company, effective October 26, 2026. The Company thanks Mr.
Biotechnology, Pharmaceuticals, Health, Psychedelics
2026-11-02 8:30 PM EST | Neural Therapeutics Inc.
InMed Announces Share Consolidation in Connection with Proposed Merger
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that, pursuant to the previously announced agreement and plan of merger and reorganization dated May 19, 2026 (as amended, the "Merger Agreement") providing for the proposed me
Biotechnology, Pharmaceuticals
2026-11-02 4:15 PM EST | Mentari Therapeutics, Inc.
Okogen Announces First Patient Dosed in Phase 1/2 EMERALD Trial Evaluating Treyegen for Acute Infectious Conjunctivitis
Plano, Texas--(Newsfile Corp. - November 2, 2026) - Okogen, Inc., a clinical-stage biotechnology company developing a host-directed antiviral platform, today announced that the first patient has been dosed in the EMERALD Trial, its multicenter Phase 1/2 clinical study evaluating Treyegen (OKG-0303) for acute infectious conjunctivitis. First dosing occurred at Ambade Eye Hospital in Nagpur, India. To view the full announcement, including downloadable images, bios, an
Biotechnology, Pharmaceuticals
2026-11-02 10:50 AM EST | Okogen
TempraMed Signs Exclusive UK Distribution Agreement with Poole Bay Holdings for VIVI Epi(TM), Targeting School Networks Across the UK
Highlights Definitive agreement signed October 28, 2026 appoints Poole Bay Holdings Ltd. as exclusive UK distributor of VIVI Epi™ for an initial 24-month term, subject to UK regulatory requirements. Contractual minimum purchase to maintain exclusivity. The initial two-year minimum volumes represent approximately US$198,000 in potential purchases. Poole Bay Holdings reports 20 specialist e-commerce sites an
Technology, Biotechnology, Pharmaceuticals, Health
2026-11-02 7:00 AM EST | TempraMed Technologies Ltd.